Literature DB >> 21074862

Clinical and immunological differences between early and late-onset myasthenia gravis in Japan.

Shigeaki Suzuki1, Kimiaki Utsugisawa, Yuriko Nagane, Takashi Satoh, Masataka Kuwana, Norihiro Suzuki.   

Abstract

Immunological characteristics of myasthenia gravis (MG) with late-onset have not been fully elucidated. We examined several autoantibodies and HLA-DRB1 genotyping in 260 Japanese MG patients. Sixty-two MG patients had thymoma. The others were divided into early-onset and late-onset groups separated by an age of 50 years. The ocular form was more frequent in late-onset compared to early-onset group. Seropositivity of anti-muscle-specific tyrosine kinase antibody was 2-3% in acetylcholine receptor-seronegative patients. HLA-DRB1 genotyping failed to detect statistical differences in specific alleles between each group and healthy controls. The immunological profiles in late-onset MG were different from early-onset in Japan.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21074862     DOI: 10.1016/j.jneuroim.2010.10.023

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

1.  Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis.

Authors:  Fredrik Romi; Shigeaki Suzuki; Norihiro Suzuki; Axel Petzold; Gordon T Plant; Nils Erik Gilhus
Journal:  J Neurol       Date:  2011-12-14       Impact factor: 4.849

2.  When do we judge IVIg for myasthenia gravis ineffective?

Authors:  Tsubasa Takizawa; Shigeaki Suzuki; Norihiro Suzuki
Journal:  Neurol Sci       Date:  2014-12-16       Impact factor: 3.307

Review 3.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

4.  Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.

Authors:  Keiko Ogawa; Yoshihiro Kozuka; Hitomi Uno; Kosuke Utsumi; Osamu Noyori; Rumiko Hosoki
Journal:  Clin Drug Investig       Date:  2021-06-10       Impact factor: 2.859

5.  Thymoma in myasthenia gravis: from diagnosis to treatment.

Authors:  Fredrik Romi
Journal:  Autoimmune Dis       Date:  2011-08-10

6.  Three types of striational antibodies in myasthenia gravis.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Norihiro Suzuki
Journal:  Autoimmune Dis       Date:  2011-07-17

7.  Analysis of serum miRNA profiles of myasthenia gravis patients.

Authors:  Gisela Nogales-Gadea; Alba Ramos-Fransi; Xavier Suárez-Calvet; Miquel Navas; Ricard Rojas-García; Jose Luis Mosquera; Jordi Díaz-Manera; Luis Querol; Eduard Gallardo; Isabel Illa
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

8.  Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis.

Authors:  Kenji Kufukihara; Yurika Watanabe; Takashi Inagaki; Koutaro Takamatsu; Shunya Nakane; Jin Nakahara; Yukio Ando; Shigeaki Suzuki
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

9.  Quality of life in purely ocular myasthenia in Japan.

Authors:  Shigeaki Suzuki; Hiroyuki Murai; Tomihiro Imai; Yuriko Nagane; Masayuki Masuda; Emiko Tsuda; Shingo Konno; Satoru Oji; Shunya Nakane; Masakatsu Motomura; Norihiro Suzuki; Kimiaki Utsugisawa
Journal:  BMC Neurol       Date:  2014-07-05       Impact factor: 2.474

Review 10.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.